RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Fleischmann, Katrin K ^a   Pagel, Philipp ^b   Schmid, Irene ^a   Roscher, Adelbert A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute myeloid leukemia; Ecopipam; Fusion gene; Gene expression; MLL AF9; Molecular processes; SCH39166; siRNA; Therapeutic targets

Indexed keywords

CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSCRIPTOME; TRANSFECTION;

EID: 84893637699     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-27     Document Type: Article

References (63)

1. Kohlmann A, Schoch C, Dugas M, Schnittger S, Hiddemann W, Kern W, Haferlach T. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 2005, 19:953-964. 10.1038/sj.leu.2403746, 15815718.
2. Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, Smith AJ, Rabbitts TH. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO Journal 1999, 18:3564-3574. 10.1093/emboj/18.13.3564, 1171435, 10393173.
3. Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008, 13:432-440. 10.1016/j.ccr.2008.03.005, 2430522, 18455126.
4. Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early human erythroid and megakaryocytic cell fate. Cell Stem Cell 2008, 2:264-273. 10.1016/j.stem.2008.01.013, 18371451.
5. Gan T, Jude CD, Zaffuto K, Ernst P. Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis. Leukemia 2010, 24:1732-1741. 10.1038/leu.2010.171, 2954260, 20724987.
6. Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y, Rabbitts TH. Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia. Mol Cell Biol 2002, 22:7313-7324. 10.1128/MCB.22.20.7313-7324.2002, 139815, 12242306.
7. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009, 94:984-993. 10.3324/haematol.2008.002436, 2704309, 19535349.
8. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010, 10:721-728. 10.1038/nrc2915, 20844554.
9. Chowdhury T, Brady HJM. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. Blood Cells Mol Dis 2008, 40:192-199. 10.1016/j.bcmd.2007.07.005, 17905612.
10. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009, 114:2489-2496. 10.1182/blood-2009-04-215152, 2927031, 19528532.
11. Rask-Andersen M, Almen MS, Schioth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011, 10:579-590. 10.1038/nrd3478, 21804595.
12. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822. 10.1038/nature04980, 16862118.
13. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78. 10.1016/j.ccr.2011.06.010, 3329803, 21741597.
14. Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, Morrone G, Vellenga E, Schuringa JJ. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia 2013, 27:1116-1126. 10.1038/leu.2012.343, 23178754.
15. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. AnnuRev Biochem 2010, 79:155-179.
16. Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia ZB, Stuart T, Diaz MO, Bushweller JH, Zeleznik L. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A 2008, 105:7517-7522. 10.1073/pnas.0800090105, 2396713, 18483194.
17. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 2010, 17:62-68. 10.1038/nsmb.1714, 2908503, 20010842.
18. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Holko M, Ayanbule O, Yefanov A, Soboleva A. NCBI GEO: archive for functional genomics data sets - 10 years on. Nucleic Acids Res 2011, 39:D1005-D1010. 10.1093/nar/gkq1184, 3013736, 21097893.
19. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
20. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J, Ribeiro RC, Rubnitz JE, Girtman K, Williams WK, Raimondi SC, Liang DC, Shih LY, Pui CH, Downing JR. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004, 104:3679-3687. 10.1182/blood-2004-03-1154, 15226186.
21. Rozovskaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, Agrawal H, Nagler A, Rappaport EF, Issaeva I, Matsuo Y, Kees UR, Lapidot T, Lo CF, Foa R, Mazo A, Nakamura T, Croce CM, Cimino G, Domany E, Canaani E. Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements. Proc Natl Acad Sci U S A 2003, 100:7853-7858. 10.1073/pnas.1132115100, 164677, 12782787.
22. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van D-K BVW, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628. 10.1056/NEJMoa040465, 15084694.
23. Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M, Fabarius A, Schatz M, Weisser A, Lorentz C, Gretz N, Hehlmann R, Hochhaus A, Seifarth W. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006, 20:1028-1034. 10.1038/sj.leu.2404227, 16617318.
24. Abrink M, Gobl AE, Huang R, Nilsson K, Hellman L. Human cell lines U-937, THP-1 and Mono Mac 6 represent relatively immature cells of the monocyte-macrophage cell lineage. Leukemia 1994, 8:1579-1584.
25. Lutherborrow M, Bryant A, Jayaswal V, Agapiou D, Palma C, Yang YH, Ma DD. Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol 2011, 86:2-11. 10.1002/ajh.21864, 20981674.
26. Klco JM, Kulkarni S, Kreisel FH, Nguyen TD, Hassan A, Frater JL. Immunohistochemical analysis of monocytic leukemias: usefulness of CD14 and Kruppel-like factor 4, a novel monocyte marker. Am J Clin Pathol 2011, 135:720-730. 10.1309/AJCPZ46PMMAWJROT, 21502426.
27. Kelly LM, Englmeier U, Lafon I, Sieweke MH, Graf T. MafB is an inducer of monocytic differentiation. EMBO Journal 2000, 19:1987-1997. 10.1093/emboj/19.9.1987, 305687, 10790365.
28. Jorgensen P, Nishikawa JL, Breitkreutz BJ, Tyers M. Systematic identification of pathways that couple cell growth and division in yeast. Science 2002, 297:395-400. 10.1126/science.1070850, 12089449.
29. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 2004, 18:227-232. 10.1038/sj.leu.2403236, 14671638.
30. Rucker FG, Sander S, Dohner K, Dohner H, Pollack JR, Bullinger L. Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia 2006, 20:994-1001. 10.1038/sj.leu.2404235, 16721385.
31. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A. Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol 2012, 5:32. 10.1186/1756-8722-5-32, 3438023, 22709827.
32. Koivusalo M, Kapus A, Grinstein S. Sensors, transducers, and effectors that regulate cell size and shape. J Biol Chem 2009, 284:6595-6599. 10.1074/jbc.R800049200, 2652343, 19004817.
33. Kawagoe H, Kawagoe R, Sano K. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1. Leukemia 2001, 15:1743-1749. 10.1038/sj.leu.2402262, 11681416.
34. Pession A, Martino V, Tonelli R, Beltramini C, Locatelli F, Biserni G, Franzoni M, Freccero F, Montemurro L, Pattacini L, Paolucci G. MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells. Oncogene 2003, 22:8671-8676. 10.1038/sj.onc.1207125, 14647461.
35. Etheridge KT, Compton SA, Barrientos KS, Ozgur S, Griffith JD, Counter CM. Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation. J Biol Chem 2008, 283:6935-6941. 10.1074/jbc.M708711200, 18178559.
36. Iakova P, Wang GL, Timchenko L, Michalak M, Pereira-Smith OM, Smith JR, Timchenko NA. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. EMBO Journal 2004, 23:406-417. 10.1038/sj.emboj.7600052, 1271759, 14726956.
37. Calzado MA, Renner F, Roscic A, Schmitz ML. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 2007, 6:139-143. 10.4161/cc.6.2.3788, 17245128.
38. Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo B, von Bergh AR, Cloos J, Kaspers GJ, De HV, Zemanova Z, Stary J, Cayuela JM, Baruchel A, Creutzig U, Reinhardt D, Pieters R, Zwaan CM, Van den Heuvel-Eibrink MM. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011, 96:1478-1487. 10.3324/haematol.2010.038976, 3186309, 21791472.
39. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113:3655-3665. 10.1182/blood-2009-01-198911, 2943835, 19221035.
40. Bunaciu RP, Yen A. Activation of the aryl hydrocarbon receptor AhR promotes retinoic acid induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res 2011, 71:2371-2380. 10.1158/0008-5472.CAN-10-2299, 3391168, 21262915.
41. Rossi M, Colecchia D, Iavarone C, Strambi A, Piccioni F, Verrotti D, Chiariello M. Extracellular signal-regulated kinase 8 (ERK8) controls estrogen-related receptor alpha (ERRalpha) cellular localization and inhibits its transcriptional activity. J Biol Chem 2011, 286:8507-8522. 10.1074/jbc.M110.179523, 3048734, 21190936.
42. Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 2009, 137:1259-1271. 10.1016/j.cell.2009.04.043, 3374131, 19563758.
43. Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, Issa JP. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999, 5:1077-1084.
44. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000, 92:1564-1572. 10.1093/jnci/92.19.1564, 11018092.
45. Schardt JA, Mueller BU, Pabst T. Activation of the unfolded protein response in human acute myeloid leukemia. Methods Enzymol 2011, 489:227-243.
46. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002, 109(Suppl):S21-S33.
47. Yan C, Higgins PJ. Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta 1835, 2013:76-85.
48. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011, 25:1628-1640. 10.1101/gad.17269211, 3182026, 21828272.
49. Spiegel A, Shivtiel S, Kalinkovich A, Ludin A, Netzer N, Goichberg P, Azaria Y, Resnick I, Hardan I, Ben Hur H, Nagler A, Rubinstein M, Lapidot T. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat Immunol 2007, 8:1123-1131. 10.1038/ni1509, 17828268.
50. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, Foley R, Leber B, Xenocostas A, Brown ED, Collins TJ, Bhatia M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297. 10.1016/j.cell.2012.03.049, 22632761.
51. Butler R, Warner M, Gustafsson J-A. Chronic myeloid leukemia in the aryl hydrocarbon receptor knockout mouse. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research 2013, Washington, DC, Philadelphia (PA), AACR; Cancer Res 2013;73(8 Suppl): Abstract nr 3858. doi:10.1158/1538-7445.AM2013-3858.
52. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39:D1035-1041. 10.1093/nar/gkq1126, 3013709, 21059682.
53. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:1-12. research0034.
54. Team RDC. R: A language and environment for statistical computing 2008, R Foundation for Statistical Computing: Vienna, Austria.
55. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
56. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:1-25. Article3.
57. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005, 397-420. New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W.
58. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J RStat Soc Series B Methodol 1995, 57:289-300.
59. Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, Chisholm RL. Annotating the human genome with disease ontology. BMC Genomics 2009, 10(1):S6.
60. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
61. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273. 10.1038/ng1180, 12808457.
62. Brinkmann M, Lutkemeyer D, Gudermann F, Lehmann J. New technologies for automated cell counting based on optical image analysis; the cellscreen. Cytotechnology 2002, 38:119-127. 10.1023/A:1021118501866, 3449924, 19003093.
63. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53:3976-3985.